| Obstacles and opportunities in the functional analysis of extracellular vesicle RNA–an ISEV position paper B Mateescu, EJK Kowal, BWM van Balkom, S Bartel, SN Bhattacharyya, ... Journal of extracellular vesicles 6 (1), 1286095, 2017 | 702 | 2017 |
| CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ... Genome research 23 (9), 1446-1461, 2013 | 679 | 2013 |
| Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts J Paggetti, F Haderk, M Seiffert, B Janji, U Distler, W Ammerlaan, YJ Kim, ... Blood, The Journal of the American Society of Hematology 126 (9), 1106-1117, 2015 | 486 | 2015 |
| Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing A Maynard, CE McCoach, JK Rotow, L Harris, F Haderk, DL Kerr, ... Cell 182 (5), 1232-1251. e22, 2020 | 410 | 2020 |
| RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ... Nature cell biology 20 (9), 1064-1073, 2018 | 324 | 2018 |
| Tumor-derived exosomes modulate PD-L1 expression in monocytes F Haderk, R Schulz, M Iskar, LL Cid, T Worst, KV Willmund, A Schulz, ... Science immunology 2 (13), eaah5509, 2017 | 290 | 2017 |
| Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment DL Kerr, F Haderk, TG Bivona Current opinion in chemical biology 62, 1-12, 2021 | 88 | 2021 |
| Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer W Wu, F Haderk, TG Bivona Cancers 9 (12), 164, 2017 | 35 | 2017 |
| Understanding drug sensitivity and tackling resistance in cancer JW Tyner, F Haderk, A Kumaraswamy, LB Baughn, B Van Ness, S Liu, ... Cancer research 82 (8), 1448-1460, 2022 | 29 | 2022 |
| Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer S Nanjo, W Wu, N Karachaliou, CM Blakely, J Suzuki, YT Chou, SM Ali, ... The Journal of clinical investigation 132 (13), 2022 | 23 | 2022 |
| Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance M Mayekar, D Caswell, N Vokes, EK Law, W Wu, W Hill, E Gronroos, ... Cancer Research 82 (12_Supplement), 2197-2197, 2022 | 18 | 2022 |
| Extracellular vesicles in chronic lymphocytic leukemia F Haderk, B Hanna, K Richter, M Schnölzer, T Zenz, S Stilgenbauer, ... Leukemia & lymphoma 54 (8), 1826-1830, 2013 | 18 | 2013 |
| Obstacles and opportunities in the functional analysis of extracellular vesicle RNA–an ISEV position paper. J Extracell Vesicles. 2017; 6: 1286095 B Mateescu, EJK Kowal, BWM van Balkom, S Bartel, SN Bhattacharyya, ... Epub 2017/03/23, 0 | 14 | |
| Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss RJ Nichols, F Haderk, C Stahlhut, CJ Schulze, G Hemmati, D Wildes, ... bioRxiv, 188730, 2017 | 13 | 2017 |
| Betacellulin drives therapy resistance in glioblastoma QW Fan, Z An, RA Wong, X Luo, ED Lu, A Baldwin, MK Mayekar, ... Neuro-oncology 22 (4), 457-469, 2020 | 11 | 2020 |
| A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer F Haderk, C Fernández-Méndez, L Čech, J Yu, IM Meraz, V Olivas, ... BioRxiv, 2021.10. 23.465573, 2021 | 10 | 2021 |
| The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ... Nature Genetics 56 (1), 60-73, 2024 | 9 | 2024 |
| Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing A Maynard, CE McCoach, JK Rotow, L Harris, F Haderk, L Kerr, EA Yu, ... BioRxiv, 2019.12. 08.868828, 2019 | 9 | 2019 |
| Immunohistochemistry to study YAP in human tissue samples F Haderk, V Olivas, TG Bivona The Hippo Pathway: Methods and Protocols, 89-95, 2019 | 7 | 2019 |
| Profiling sensitivity to targeted therapies in EGFR-mutant NSCLC patient-derived organoids DB Rabago, CM Blakely, F Haderk, TG Bivona JoVE (Journal of Visualized Experiments), e63039, 2021 | 5 | 2021 |
